Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

NCT06065462 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Clear Cell Carcinoma

Interventions

DRUG: Dostarlimab
DRUG: LB-100

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]